The proportion of CXCR4 overexpression was the highest in pancreatic NEC patients (66.7%), followed by colorectal (57.1%), gallbladder (50.0%), esophagus (25.0%) and stomach (15.0%). Here, CXCR4 is linked to pancreatic endocrine carcinoma.